Disclosed CapitolDisclosedCapitol
Home
Plans
Chad AI
API
Sign InGet Pro

Never Miss a Trade

Get weekly trade alerts free.

Explore

  • Politician Trades
  • Politicians
  • Executive Branch
  • Companies
  • All Stocks A–Z
  • Leaderboard
  • Compare Politicians
  • Committee Portfolios
  • Chad AI

Money & Policy

  • Government Contracts
  • Lobbying
  • Legislation
  • Campaign Finance
  • Institutional (13F)
  • Whale Watch (13D)

Markets

  • Markets Overview
  • Top Companies
  • Insider Trends
  • Economic Indicators
  • Live News

Resources

  • API Access
  • Developers
  • Data Export
  • Glossary
  • Methodology
  • Data Sources
  • How It Works

Company

  • About Us
  • Press
  • FAQ
  • Pricing
  • vs. Capitol Trades
  • Contact
  • Watchlist

Legal

  • Editorial Standards
  • Corrections
  • Disclaimers
  • Privacy
  • Terms
© 2026 Disclosed Capitol. All rights reserved.
TermsPrivacyDisclaimer
HomeTrades
Chad
WatchlistAccount

UTHR

Healthcare
United Therapeutics Corporation · Drug Manufacturers - Specialty & Generic
Trades
46
Politicians
0
Buys
9
Sells
31
Trades
46
Politicians
0
Buys
9
Sells
31
UTHRvs S&P 500 (normalized)
|to
No price data available
UTHR S&P 500 Buy Sell
Range
PoliticianActionDescriptionAmountTradedFiled
Ro KhannaD
SellUNITED THERAPEUTICS CORP CMN$1K - $15KFeb 5, 2026Mar 9, 2026
Lisa McClainR
SellUnited Therapeutics Corporat$1K - $15KOct 31, 2025Nov 21, 2025
Lisa McClainR
BuyUnited Therapeutics Corporat$1K - $15KOct 30, 2025Nov 21, 2025
Lisa McClainR
SellUnited Therapeutics Corporat$1K - $15KOct 30, 2025Nov 21, 2025
Michael McCaulR
SellUNITED THERAPEUTICS CORP$1K - $15KAug 22, 2025Sep 11, 2025
Michael McCaulR
BuyUNITED THERAPEUTICS CORP$15K - $50KAug 7, 2025Sep 11, 2025
Michael McCaulR
SellUNITED THERAPEUTICS CORP$1K - $15KJun 27, 2025Jul 7, 2025
Lisa McClainR
BuyUnited Therapeutics Corporat$1K - $15KJun 11, 2025Aug 13, 2025
Ro KhannaD
SellUNITED THERAPEUTICS CMN$1K - $15KFeb 25, 2025Mar 6, 2025
Michael McCaulR
SellUNITED THERAPEUTICS CORP$1K - $15KNov 20, 2024Dec 5, 2024
46 trades
…

United Therapeutics Corporation (UTHR) Congressional Stock Trades

This page tracks congressional stock trading activity in United Therapeutics Corporation (UTHR) in the Healthcare sector. Disclosed Capitol has indexed 46 disclosed congressional trades involving UTHR. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.

As of March 2026 — Disclosed Capitol has tracked 46 disclosed congressional trades in United Therapeutics Corporation (UTHR) — 31:9 sell-heavy ratio — led by Michael McCaul (R).

Which members of Congress trade United Therapeutics Corporation?

  • Michael McCaul (R) — 37 disclosed trades in UTHR
  • Lisa McClain (R) — 4 disclosed trades in UTHR
  • Ro Khanna (D) — 3 disclosed trades in UTHR
  • Donna Shalala (D) — 1 disclosed trade in UTHR
  • Thomas MacArthur (R) — 1 disclosed trade in UTHR

Recent UTHR congressional trades

DatePoliticianPartyActionAmount
Feb 5, 2026Ro KhannaDSell$1,001 - $15,000
Oct 31, 2025Lisa McClainRSale$1,001 - $15,000
Oct 30, 2025Lisa McClainRBuy$1,001 - $15,000
Oct 30, 2025Lisa McClainRSale$1,001 - $15,000
Aug 22, 2025Michael McCaulRSale$1,001 - $15,000
Aug 7, 2025Michael McCaulRPurchase$15,001 - $50,000
Jun 27, 2025Michael McCaulRSale$1,001 - $15,000
Jun 11, 2025Lisa McClainRBuy$1,001 - $15,000
Feb 25, 2025Ro KhannaDSale$1,001 - $15,000
Nov 20, 2024Michael McCaulRExchange$1,001 - $15,000

Buy vs. sell ratio & volume

Across the 46 disclosed congressional trades in United Therapeutics Corporation (UTHR), members of Congress have reported 9 buys and 31 sells. The average 30-day alpha vs. the S&P 500 is -1.29%.

Are United Therapeutics Corporation insiders buying or selling UTHR?

As of August 2026, corporate insiders at United Therapeutics Corporation have filed 888 SEC Form 4 transactions in UTHR over the past 12 months — including 1 open-market buy worth $864K and 776 sells worth $397.7M.

DateInsiderActionValue
2026-08-27ROTHBLATT MARTINE A — Chairperson & CEOOption Exercise$1.3M
2026-08-27ROTHBLATT MARTINE A — Chairperson & CEOSale$253K
2026-08-27ROTHBLATT MARTINE A — Chairperson & CEOSale$329K
2026-08-27ROTHBLATT MARTINE A — Chairperson & CEOSale$361K
2026-08-27ROTHBLATT MARTINE A — Chairperson & CEOSale$62K
2026-08-27ROTHBLATT MARTINE A — Chairperson & CEOSale$124K
2026-08-27ROTHBLATT MARTINE A — Chairperson & CEOSale$145K
2026-08-27ROTHBLATT MARTINE A — Chairperson & CEOSale$104K
2026-08-27ROTHBLATT MARTINE A — Chairperson & CEOSale$522K
2026-08-27ROTHBLATT MARTINE A — Chairperson & CEOSale$249K

Insider transactions are parsed from SEC Form 4 filings and shown alongside the congressional trades above. Institutional 13F positions are tracked separately on the institutional holdings page.

Does United Therapeutics Corporation receive U.S. government contracts?

As of April 2026, United Therapeutics Corporation has 107 federal contract award records on file from USAspending.gov — most recently -$271K from the Department of Veterans Affairs on 2026-04-22.

Award dateAgencyAmount
2026-04-22Department of Veterans Affairs-$271K
2025-10-20Department of Veterans Affairs$108K
2025-10-14Department of Veterans Affairs$379K
2025-06-05Department of Veterans Affairs-$90K
2025-05-01Department of Veterans Affairs-$88K
2025-04-16Department of Veterans Affairs-$73K
2025-01-24Department of Veterans Affairs-$73K
2025-01-21Department of Veterans Affairs$90K
2024-10-08Department of Veterans Affairs$88K
2024-06-12Department of Veterans Affairs$59K

Negative amounts are contract de-obligations. Browse and filter every award on the government contracts page.

United Therapeutics Corporation financial snapshot (FY2025)

For fiscal year 2025, United Therapeutics Corporation reported revenue of $3.18B and net income of $1.33B, per SEC filings.

Revenue
$3.18B
Gross profit
$2.80B
Operating income
$1.49B
Net income
$1.33B
Diluted EPS
$27.86
Gross margin
87.9%
Net margin
41.9%
Free cash flow
$1.04B

Most recent reported quarter: Q2 FY2026 — revenue $783.3M, net income $333.0M.

Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.